Roivant says IMVT-1402 cutaneous lupus study misses primary endpoint, halts development in CLE

By Public Technologies
  • Roivant reported topline results from a proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus.
  • Results have already been presented as topline data, showing the trial missed its main efficacy goal versus placebo.
  • Secondary measures showed encouraging directional signals, particularly in patients with stronger biological responses.
  • Development in cutaneous lupus will be halted, citing the overall readout and a competitive market backdrop.
  • Safety was described as favorable, with other IMVT-1402 programs kept on their existing clinical timelines.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230700PRIMZONEFULLFEED9832408) on September 23, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk